

Cancer Genetics and Genomics for Personalized Medicine

edited by **Il-Jin Kim**



Cancer Genetics and Genomics for Personalized Medicine

Taylor & Francis
Taylor & Francis Group
http://taylorandfrancis.com

Cancer Genetics and Genomics for Personalized Medicine

edited by

Il-Jin Kim

Published by

Pan Stanford Publishing Pte. Ltd.
Penthouse Level, Suntec Tower 3
8 Temasek Boulevard
Singapore 038988

Email: editorial@panstanford.com
Web: www.panstanford.com

British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library.

Cancer Genetics and Genomics for Personalized Medicine

ISBN 978-981-4669-87-0 (Hardcover)
ISBN 978-1-315-36476-6 (eBook)

Printed in the USA

Contents

Preface xiii

1 Personalized Medicine for Cancer: Introduction and Overview of the Book **1**
Il-Jin Kim and David Jablons
1.1 Changing the Treatment Paradigm for Cancer 1
1.2 Companion Diagnostics and New Sequencing Technologies 3
1.3 Early Detection of Cancer and Tumor Recurrence Monitoring: Circulating Tumor Cell (CTC) and Circulating Tumor DNA (ctDNA) 5
1.4 Cancer Animal (Mouse) Models and Microenvironment for Personalized Medicine 6
1.5 Personalized Immunotherapy 7
1.6 Hereditary Cancer Syndromes and Potential Treatment 7
1.7 Future Directions 8

2 Personalized Medicine in Lung Cancer **15**
Daniela Morales-Espinosa, Silvia García-Román, and Rafael Rosell
2.1 Introduction 15
2.1.1 Predictive Models 16
2.1.2 The Molecular Diagnostics Approach 17
2.1.3 Conventional Chemotherapy 19
2.1.3.1 Cisplatin 19
2.1.3.2 Pemetrexed 20

2.1.3.3 Gemcitabine 21
2.1.3.4 Taxanes 22
2.2 Genetic Alterations and New Potential Targets 23
2.2.1 Receptor Tyrosine Kinases 24
2.2.1.1 EGFR inhibitors (first and second generation) 24
2.2.1.2 ALK rearrangement (first and second generation) 25
2.2.1.3 ROS1 26
2.2.2 Epigenetic Factors 27
2.2.3 Transcription Factors 30
2.2.4 Repurposing Drugs 32
2.3 Conclusions 33

3 Genome-Based Personalized Medicine in Liver Cancer 39
Jae-Jun Shim and Ju-Seog Lee
3.1 Introduction 39
3.1.1 Epidemiology of Liver Cancer 39
3.1.2 Clinical Characteristics of Liver Cancer 40
3.2 Why Personalized Medicine is Important in Patients with Liver Cancer? 41
3.3 Methods and Results of Genomic Profiling of Liver Cancer 42
3.3.1 Comparative Genomic Hybridization (CGH) 42
3.3.2 Microarray-Based Technology 43
3.3.3 Next-Generation Sequencing 44
3.3.4 Integromics: Integration of Multiple -omic Data 45
3.4 Conclusion 47

4 Applications of Circulating DNA Analysis in Personalized Medicine 53
Dana W. Y. Tsui and Muhammed Murtaza
4.1 Biological Characteristics of Circulating DNA 53
4.1.1 History 53
4.1.2 Biological Characteristics 54
4.2 Molecular Methods for Circulating DNA Analysis 55
4.3 Circulating Tumor-Specific DNA in Cancer Patients 58

4.3.1 Monitoring of Tumor Burden and Disease Response 58
4.3.2 Molecular Stratification for Targeted Therapies 59
4.3.3 Analysis of Clonal Evolution and Therapeutic Resistance 60
4.4 Circulating DNA for Noninvasive Prenatal Diagnostics 60
4.4.1 Noninvasive Diagnosis of Fetal Genetic Diseases 61
4.4.2 Noninvasive Prenatal Diagnosis of Down-Syndrome 61
4.4.3 Noninvasive Sequencing of the Fetal Genome 62
4.4.4 Clinical Implementation of Prenatal Diagnosis 63
4.5 Circulating DNA in Transplant Recipients 63
4.6 Pre-analytical Considerations 63
4.7 Conclusion 65

5 Circulating Tumor Cells and Personalized Medicine 77
Jin Sun Lee, Mark Jesus M. Magbanua, Marc R. Jabon, and John W. Park
5.1 Metastasis and Circulating Tumor Cells 77
5.1.1 The Metastatic Process 78
5.1.2 Circulating Tumor Cells 79
5.2 Enrichment and Detection of CTCs 79
5.2.1 Enrichment 80
5.2.2 Detection 82
5.2.2.1 Immuno-cytomorphological approach: Immunocytochemistry (ICC) 82
5.2.2.2 Molecular approach: Real-time reverse transcription polymerase chain reaction (RT-PCR) 84
5.3 Clinical Implications of CTC Detection and Enumeration 84
5.3.1 Breast Cancer 85
5.3.2 Prostate Cancer 86
5.3.3 Colorectal Cancer 87
5.3.4 Lung Cancer 88
5.4 Molecular Characterization of CTC and Personalized Medicine 89

5.4.1 Tumor Biomarkers in CTCs 89
5.4.2 Molecular Analysis of CTCs 90
5.4.3 Clinical Trials for Personalized Medicine 90
5.5 Summary 92

6 Mouse Models in Personalized Cancer Medicine 103
M. E. Beaulieu, T. Jauset, D. Massó-Vallés, L. Soucek, and J. R. Whitfield
6.1 Transgenic Mouse Models: From Understanding the Molecular Basis of Tumorigenesis to the Refinement of Drug Design Targeting Specific Mutated/Altered Proteins 104
6.1.1 Prenatal GEMMs 105
6.1.1.1 Tissue-specific promoters and CRE recombinase technology 105
6.1.2 Postnatal GEMMS 107
6.1.2.1 Irreversible models: Inducible CRE recombination 107
6.1.2.2 Switchable models: The tetracycline inducible system 108
6.1.2.3 The estrogen-receptor system 110
6.1.3 GEMMs: Benefits and Drawbacks 111
6.2 Patient-Derived Xenograft (PDX): Tumor Heterogeneity and the Exploration of Avatars as Predictors of Treatment Outcome 112
6.2.1 Starting Material 113
6.2.2 Mode of Implantation 115
6.2.3 Recipient Mouse Strains 116
6.2.4 PDXs in Personalized Medicine 117
6.2.5 PDXs: Limitations and Value 121
6.3 Humanized Mouse Models: Bringing the Major Players Back into the Biological Game 122
6.3.1 The Need for Better Models 122
6.3.2 “Humanizing” the Mouse Models 123
6.3.3 Transplantation of Hematopoietic Stem Cells 124
6.3.4 Transplantation of Peripheral Blood Mononuclear Cells 125
6.3.5 Local “Humanization” 125

6.3.6 Overcoming Limitations of the Model 126
6.3.7 Success Stories 126
6.3.8 Humanized Mouse Models: Future Perspectives 128
6.4 Discussion and Perspectives 128

7 Tumor Microenvironment, Therapeutic Resistance, and Personalized Medicine 145
Yu Sun
7.1 TME Orchestrates Disease Progression and Dominates Therapeutic Response 146
7.1.1 Cancer-Associated Fibroblasts 147
7.1.2 Vasculature System 148
7.1.3 Extracellular Matrix 148
7.1.4 Immune Cells 149
7.1.5 TME-Derived Exosomes 151
7.2 Treatment-Activated TME Confers Acquired Resistance and Creates Barriers to a Clinical Cure 154
7.2.1 Damage Responses of the TME Offset Therapy-Enforced Tumor Regression 154
7.2.2 Modified Differentiation and Immune Responses in the TME Decrease Therapeutic Outcomes 157
7.3 Overcoming Challenges of Personalized Cancer Therapy Requires Translation of Biological Insights into the Clinic 158
7.3.1 Implications of Personalized Cancer Therapy in an Era of Precision Medicine 158
7.3.2 Significance of Preclinical Studies in Promoting PCT Advancement 163
7.4 Concluding Remarks and Future Outlooks 165

8 Personalized Immune Therapy 175
Joost Hegmans, Lysanne Lievense, and Joachim Aerts
8.1 Immunotherapy 176
8.2 Immune Cell Involvement during Carcinogenesis 177
8.3 Context-Specific Nature of Immune Cells within Tumors 177

8.4 Types of Immunotherapeutic Approaches 179
8.4.1 Biological Response Modifiers 180
8.4.2 Monoclonal Antibodies 180
8.4.3 Tumor Vaccines 181
8.4.4 Cellular Immunotherapy 181
8.4.4.1 Dendritic cell-based immunotherapy 182
8.4.4.2 Adoptive genetically modified and/or expanded T-cell therapy 182
8.4.4.3 Adoptive natural killer (T) cells' transfer 183
8.5 The Future of Personalized Medicine 183

9 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Malignancies 189
G. E. Bates, P. Kim, C. M. DeRosa, L. Petrukhin, Y. Bressler, and R. N. Taub
9.1 What Is Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? 189
9.2 The Role of Heat as a Cytotoxic Agent 191
9.3 The Role of Heat Shock Proteins in HIPEC Treatment 192
9.4 Chemotherapeutic Agents Used for HIPEC 193
9.4.1 Cisplatin: [cis-diamminedichloroplatinum(II) (CDDP)] (Platinol and Platinol-AQ) 193
9.4.2 Doxorubicin: (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione) 194
9.4.3 Carboplatin: (cis-diammine-1,1-cyclobutane dicarboxylate platinum II, CBDCA, JM8) 195
9.4.4 Melphalan: 4-[bis(chloroethyl)amino] phenylalanine] 195
9.5 Quality-of-Life Impact of HIPEC Treatment 196
9.6 The Future of HIPEC: The Need for Personalization 197

10 Personalized Medicine in Hereditary Cancer Syndromes 199
Rishi Agarwal and Vivek Subbiah
10.1 Introduction 199
10.2 Neurofibromatosis Type 1 201
10.3 Neurofibromatosis Type 2 203
10.4 Gorlin Syndrome 204
10.5 Hereditary Breast and Ovarian Cancer Syndrome 205
10.6 Lynch Syndrome 208
10.7 Familial Adenomatous Polyposis 208
10.8 Fanconi Anemia 210
10.9 Inherited Medullary Thyroid Cancer 211
10.10 Tuberous Sclerosis Complex (TSC) 212
10.11 RASopathies 213
10.12 Von Hippel–Lindau Disease 214
10.12.1 Tyrosine Kinase Inhibitors (TKIs) 215
10.12.2 mTOR Inhibitors 216
10.12.3 Anti-VEGF Receptor Antibodies 216
10.12.4 Other Agents Including Histone Deacetylases (HDAC) Inhibitor 217
10.13 Cowden Syndrome 217
10.14 Proteus and Proteus-Like Syndrome 218
10.15 Li–Fraumeni Syndrome 218
10.16 Conclusions 219

11 Pathology in the Era of Personalized Medicine 227
Hye Seung Lee
11.1 Why Is the Role of Pathologists in Personalized Medicine Important? 228
11.2 Practical Guidance for Molecular Pathology 229
11.2.1 Preanalytic 229
11.2.2 Analytic 230
11.2.3 Quality Assurance 232
11.2.4 Postanalytic 233
11.3 Next-Generation Sequencing and the Pathologist 234
11.4 Conclusions 235

12 MicroRNAs in Human Cancers **239**
Tae Jin Lee and Carlo M. Croce
12.1 Introduction 239
12.2 Biogenesis and Working Mechanism of MicroRNA 242
12.3 MicroRNAs as Tumor Suppressors 244
12.4 MiRNAs as Oncogenes 245
12.5 MiRNAs and Epigenetics 247
12.6 MiRNA Signatures in Human Cancers 248
12.7 Biomarker MiRNAs in Human Cancers 249
12.8 Circulating MiRNAs as Biomarkers of Human Cancers 251
12.9 Single Polymorphism (SNP) in MiRNAs 252
12.10 MiRNA and Cancer Stem Cells 253
12.11 Perspectives 253

13 Pharmacogenomics of Tamoxifen **265**
Hitoshi Zembutsu
13.1 What Is Tamoxifen? 266
13.2 Why Is Pharmacogenomics of Tamoxifen Important? 266
13.2.1 Metabolic Pathway of Tamoxifen 267
13.2.2 *CYP2D6* Genotype and Pharmacokinetics of Tamoxifen 269
13.2.3 *CYP2D6* Genotype and Tamoxifen Efficacy 269
13.3 The Controversy in Tamoxifen-*CYP2D6* Study 270
13.4 Future Direction of Tamoxifen Pharmacogenomics 271
13.4.1 Pharmacogenomics for Irinotecan: *UGT1A1* 271
13.4.2 Pharmacogenetic Test of *CYP2C9* and *VKORC1* Genotypes for Warfarin Treatment 272

Index 279

Preface

On a busy morning one day, I got an email from a publisher asking for a new publication on precision and personalized medicine for cancer treatment and research. By that time, I had led several relevant projects, including the development of new next-generation sequencing (NGS) technologies and corresponding bioinformatics programs. There were surely successful and commercial products developed from these projects (which are now available in the genetic analysis market in the world), yet I was not sure if I would be able to write or edit a textbook on a big topic like personalized medicine. Previously, I only had had a chance to join two scientific books as a single-chapter contributor, but had never written or edited a whole book by myself. It seemed quite overwhelming to me at the time. However, as several months passed since I received the first email about this opportunity, I began to open my mind and be more positive towards the idea. In fact, I had been working on personalized medicine, cancer genetics, companion diagnostics, and cancer biomarker discovery for more than 15 years by then. Thus, I thought it would be good to organize and integrate all the knowledge that I have along with that which top-level scientists, researchers, and medical doctors have been gathering regarding personalized medicine in cancer. Consequently, I gladly decided to embark on this project even though I was very busy developing multiple new sequencing and genetic technologies. First, I tried to select the topics that could be the most beneficial for the people engaged in training such as graduate students, medical residents, and other high-level professionals who are relatively unfamiliar with personalized medicine. The next thing I did was the most time-consuming and challenging work—finding the most suitable people who can write on the topic with up-to-date knowledge and information in a plain

language. As a matter of fact, it took me almost an entire year to find all the world-class authors for each chapter. I really appreciate all the contributors of each chapter in this book. Without their contribution and efforts, the book could not have been published. I thank them for their patience and support because it took much longer than expected to finally get this book published. I also appreciate my good friend and colleague Pedro Mendez, who designed the cover for this book. I must say that he is the most artistic person I have ever met in my group. I also thank James Kim for his editorial assistance and sincere friendship. I thank the whole team at the UCSF Thoracic Oncology Program and CureSeq for their support and inspiration on precision medicine and companion diagnostics in developing new weapons (the world's fastest mutation screening assay) fighting cancer. Finally, I thank Stanford Chong greatly for suggesting and giving me a chance to publish this book, and Sarabjeet Garcha for all the help and communication.

I would like to offer my wholehearted gratitude to my family who supported me not only in the writing of this book but also in all my work in general. My parents, Ho-Young Kim and Yong-Soon Bang, in Korea taught me well to maintain a strong passion for my life's goals, and also to give endless love to my family. My wife, Hio Chung Kang, and my two sons, Thomas Kunhee and Benjamin Kunjune Kim, are truly the very source of all my sweat, effort, motivation, and energy behind the achievements.

We are already in the era of personalized and precision medicine for curing cancer. Technologies and methods will develop continuously and evolve rapidly. However, grasping the core concept and principles will constantly remain crucial until we finally cure cancer. I really hope this book will be helpful and informative to current and future heroes and heroines in their fight against, and the eventual conquest over, cancer.

Il-Jin Kim
February 2017
San Francisco